The U.S. Food and Drug Administration (FDA) has approved Takeda's oveporexton to be marketed as Orzeyful for the treatment of adults with narcolepsy type 1 (NT1). The approval marks a significant milestone because the therapy targets the underlying biology of the disorder rather than focusing solely on symptom control, representing a new approach to treating narcolepsy.
According to news reports, Ovsid is the first FDA-approved orexin receptor 2 (OX2R) agonist for narcolepsy type 1. The disorder is characterized by the loss of orexin-producing neurons in the brain, leading to excessive daytime sleepiness, cataplexy, and disrupted sleep. By activating the orexin pathway, the drug is designed to address the biological mechanism responsible for these symptoms instead of simply helping patients manage them.
